Phase II trial of AGS 003 for the treatment of non-clear cell metastatic renal cell carcinoma

Trial Profile

Phase II trial of AGS 003 for the treatment of non-clear cell metastatic renal cell carcinoma

Planning
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2015

At a glance

  • Drugs Rocapuldencel-T (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2014 New trial record
    • 13 May 2014 Argos Therapeutics intends to devote its cash, cash equivalents and short term investments to fund its planned phase 2 clinical trial of AGS 003 in non-clear cell mRCC.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top